# OnCo record idea-adc-for-mesothelioma (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-adc-for-mesothelioma/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-adc-for-mesothelioma" ;
  schema:name "Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work"@en ;
  schema:description "Nearly every mesothelioma carries the surface protein mesothelin, yet the one antibody-drug conjugate tried in a randomised trial did no better than chemotherapy. The idea is to fix the three reasons it failed rather than abandon the approach."@en ;
  schema:url <https://onco.cc/ideas/idea-adc-for-mesothelioma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(22)00061-4>, <https://clinicaltrials.gov/study/NCT03126630>, <https://clinicaltrials.gov/study/NCT05579366> ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/mesothelin/> ;
  onco:drugs <https://onco.cc/drugs/anetumab-ravtansine/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:trials <https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/>, <https://onco.cc/trials/nci-anetumab-pembrolizumab-mpm/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kindler-lancet-oncol/>, <https://onco.cc/key-papers/paper-mesothelin-mesothelioma-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/>, <https://onco.cc/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/> .